Triple-negative breast cancers (TNBC), which account for about 10–20% of breast cancer (1), are defined as tumors that lack the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (2). This evidence concerns the gene PGR and triple-negative breast carcinoma.